Dysregulation of circRNA-0076906 and circRNA-0134944 is Correlated with Susceptibility to Osteoporosis and Osteoporotic Fracture in Postmenopausal Females from the Chinese Han Population

References

• Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med. 2017;167:ITC17–ITC32. doi:10.7326/AITC201708010
   PubMed Web of Science ®Google Scholar
• Black DM, Rosen CJ. Postmenopausal Osteoporosis. N Engl J Med. 2016;374:2096–2097. doi:10.1056/NEJMcp1513724
   PubMedGoogle Scholar
• Black DM, Rosen CJ, Solomon CG. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–262.
   PubMed Web of Science ®Google Scholar
• Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5:898–907. doi:10.1016/S2213-8587(17)30188-2
   PubMed Web of Science ®Google Scholar
• Brown C. Osteoporosis: staying strong. Nature. 2017;550:S15–S17. doi:10.1038/550S15a
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541. doi:10.1016/S0140-6736(96)07088-2
   PubMed Web of Science ®Google Scholar
• Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243–254. doi:10.1002/jbmr.1494
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:1923–1934. doi:10.1359/jbmr.080710
   PubMed Web of Science ®Google Scholar
• Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721–739. doi:10.1359/jbmr.2000.15.4.721
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, De Laet C, et al. Tenenhouse A: a meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35:375–382. doi:10.1016/j.bone.2004.03.024
   PubMed Web of Science ®Google Scholar
• Turnbull F. Blood pressure lowering treatment trialists C: effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–1535.
   PubMed Web of Science ®Google Scholar
• Duell PB, Santos RD, Kirwan BA, Witztum JL, Tsimikas S, Kastelein JJP. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. J Clin Lipidol. 2016;10:1011–1021. doi:10.1016/j.jacl.2016.04.013
   PubMed Web of Science ®Google Scholar
• Han B, Chao J, Yao H. Circular RNA and its mechanisms in disease: from the bench to the clinic. Pharmacol Ther. 2018;187:31–44. doi:10.1016/j.pharmthera.2018.01.010
   PubMed Web of Science ®Google Scholar
• Salzman J. Circular RNA expression: its potential regulation and function. Trends Genet. 2016;32:309–316. doi:10.1016/j.tig.2016.03.002
   PubMed Web of Science ®Google Scholar
• Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–388. doi:10.1038/nature11993
   PubMed Web of Science ®Google Scholar
• Zheng Q, Bao C, Guo W, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun. 2016;7:11215. doi:10.1038/ncomms11215
   PubMed Web of Science ®Google Scholar
• Wen J, Guan Z, Yu B, Guo J, Shi Y, Hu L. Circular RNA hsa_circ_0076906 competes with OGN for miR-1305 biding site to alleviate the progression of osteoporosis. Int J Biochem Cell Biol. 2020;122:105719. doi:10.1016/j.biocel.2020.105719
   PubMed Web of Science ®Google Scholar
• Zhang DW, Chen T, Li JX, Wang HG, Huang ZW, Lv H. Circ_0134944 inhibits osteogenesis through miR-127-5p/PDX1/SPHK1 pathway. Regen Ther. 2021;18:391–400. doi:10.1016/j.reth.2021.09.004
   PubMed Web of Science ®Google Scholar
• Kaji H. Interaction between Muscle and Bone. J Bone Metab. 2014;21:29–40. doi:10.11005/jbm.2014.21.1.29
   PubMedGoogle Scholar
• Tanaka K, Matsumoto E, Higashimaki Y, et al. Role of osteoglycin in the linkage between muscle and bone. J Biol Chem. 2012;287:11616–11628. doi:10.1074/jbc.M111.292193
   PubMed Web of Science ®Google Scholar
• Chen X, Chen J, Xu D, Zhao S, Song H, Peng Y. Effects of Osteoglycin (OGN) on treating senile osteoporosis by regulating MSCs. BMC Musculoskelet Disord. 2017;18:423. doi:10.1186/s12891-017-1779-7
   PubMed Web of Science ®Google Scholar
• Kaleta B, Walicka M, Sawicka A, et al. Toll-like receptor 4 gene polymorphism C1196T in Polish women with postmenopausal osteoporosis - preliminary investigation. Adv Clin Exp Med. 2015;24:239–243. doi:10.17219/acem/22747
   PubMed Web of Science ®Google Scholar
• Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116:3015–3025. doi:10.1172/JCI28898
   PubMed Web of Science ®Google Scholar
• Yu L, Liu Y. circRNA_0016624 could sponge miR-98 to regulate BMP2 expression in postmenopausal osteoporosis. Biochem Biophys Res Commun. 2019;516(2):546–550. doi:10.1016/j.bbrc.2019.06.087
   PubMed Web of Science ®Google Scholar
• Li X, Wu J, Liu S, et al. miR-384-5p targets Gli2 and negatively regulates age-related osteogenic differentiation of rat bone marrow mesenchymal stem cells. Stem Cells Dev. 2019;28:791–798. doi:10.1089/scd.2019.0044
   PubMed Web of Science ®Google Scholar
• Lee JY, Eom EM, Kim DS, Ha-Lee YM, Lee DH. Analysis of gene expression profiles of gastric normal and cancer tissues by SAGE. Genomics. 2003;82:78–85. doi:10.1016/S0888-7543(03)00098-3
   PubMed Web of Science ®Google Scholar
• Wang Y, Ma Y, Lu B, Xu E, Huang Q, Lai M. Differential expression of mimecan and thioredoxin domain-containing protein 5 in colorectal adenoma and cancer: a proteomic study. Exp Biol Med. 2007;232:1152–1159. doi:10.3181/0701-RM-8
   PubMed Web of Science ®Google Scholar
• Rower C, Ziems B, Radtke A, et al. Toponostics of invasive ductal breast carcinoma: combination of spatial protein expression imaging and quantitative proteome signature analysis. Int J Clin Exp Pathol. 2011;4:454–467.
   PubMed Web of Science ®Google Scholar
• Chan CY, Masui O, Krakovska O, et al. Identification of differentially regulated secretome components during skeletal myogenesis. Mol Cell Proteomics. 2011;10:M110 004804. doi:10.1074/mcp.M110.004804
   PubMed Web of Science ®Google Scholar
• Patel MJ, Liu W, Sykes MC, et al. Identification of mechanosensitive genes in osteoblasts by comparative microarray studies using the rotating wall vessel and the random positioning machine. J Cell Biochem. 2007;101:587–599. doi:10.1002/jcb.21218
   PubMed Web of Science ®Google Scholar
• Zambotti A, Makhluf H, Shen J, Ducy P. Characterization of an osteoblast-specific enhancer element in the CBFA1 gene. J Biol Chem. 2002;277:41497–41506. doi:10.1074/jbc.M204271200
   PubMed Web of Science ®Google Scholar
• Kawaguchi H, Akune T, Yamaguchi M, et al. Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. J Bone Miner Metab. 2005;23:275–279. doi:10.1007/s00774-005-0599-2
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394–397. doi:10.1038/41131
   PubMed Web of Science ®Google Scholar
• Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med. 2009;15:774–780. doi:10.1038/nm.1987
   PubMed Web of Science ®Google Scholar
• Wang P, Zhu F, Tong Z, Konstantopoulos K. Response of chondrocytes to shear stress: antagonistic effects of the binding partners Toll-like receptor 4 and caveolin-1. FASEB J. 2011;25:3401–3415. doi:10.1096/fj.11-184861
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Matsuguchi T, Tsuboi N, et al. Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. J Immunol. 2001;166:3574–3579. doi:10.4049/jimmunol.166.5.3574
   PubMed Web of Science ®Google Scholar
• Nemoto E, Honda T, Kanaya S, Takada H, Shimauchi H. Expression of functional Toll-like receptors and nucleotide-binding oligomerization domain proteins in murine cementoblasts and their upregulation during cell differentiation. J Periodontal Res. 2008;43:585–593. doi:10.1111/j.1600-0765.2008.01096.x
   PubMed Web of Science ®Google Scholar
• Mo IF, Yip KH, Chan WK, Law HK, Lau YL, Chan GC. Prolonged exposure to bacterial toxins downregulated expression of toll-like receptors in mesenchymal stromal cell-derived osteoprogenitors. BMC Cell Biol. 2008;9:52. doi:10.1186/1471-2121-9-52
   PubMedGoogle Scholar
• Vijayan V, Khandelwal M, Manglani K, Gupta S, Surolia A. Methionine down-regulates TLR4/MyD88/NF-kappaB signalling in osteoclast precursors to reduce bone loss during osteoporosis. Br J Pharmacol. 2014;171:107–121. doi:10.1111/bph.12434
   PubMed Web of Science ®Google Scholar